Literature DB >> 10198488

A community survey of patients with atrial fibrillation: associated disabilities and treatment preferences.

M Sudlow1, R Thomson, R A Kenny, H Rodgers.   

Abstract

BACKGROUND: Anticoagulants are effective in preventing stroke in those with atrial fibrillation, but most patients remain untreated. AIM: To investigate the prevalence of disability, cognitive impairment, and problems with compliance in a representative sample of the elderly with atrial fibrillation, and to determine whether they would want treatment and how they would like services to be arranged.
METHOD: In a survey of a random sample of 4843 elderly subjects, those with atrial fibrillation were identified using electrocardiograms. Views on treatment were obtained using a structured interview. Disability was assessed using the Office of Population Censuses and Surveys Disability Scale and cognitive status using the Mini Mental State Examination. General practitioners were asked, via questionnaire, for their views on each subject's compliance.
RESULTS: Two hundred and seven elderly people with atrial fibrillation were identified. Almost all subjects expressed a willingness to undertake treatment to prevent stroke and preferred blood testing performed outside of hospital. Disability (82.7%), cognitive impairment (25.7%), and problems with compliance (25.0%) were common, but the prevalence of these difficulties was not substantially different from the general elderly population, and in many cases they could be overcome (e.g. only 10% of subjects had problems with compliance and no-one who could help them to comply).
CONCLUSIONS: Most elderly people with atrial fibrillation would accept treatment to prevent stroke. Disability, cognitive impairment, and problems with compliance may make it difficult to treat this patient group. An increase in the use of anticoagulants should be accompanied by the development of services appropriate to this frail population.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10198488      PMCID: PMC1313272     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  17 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

Review 2.  The mini-mental state examination: a comprehensive review.

Authors:  T N Tombaugh; N J McIntyre
Journal:  J Am Geriatr Soc       Date:  1992-09       Impact factor: 5.562

3.  Antithrombotic therapy prescribed for patients with non-rheumatic atrial fibrillation.

Authors:  A Hendry; A M Campbell; G Campbell; J B Macdonald; B O Williams
Journal:  Scott Med J       Date:  1994-08       Impact factor: 0.729

4.  A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project.

Authors:  G Y Lip; D J Golding; M Nazir; D G Beevers; D L Child; R I Fletcher
Journal:  Br J Gen Pract       Date:  1997-05       Impact factor: 5.386

5.  Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

Authors:  P Petersen; G Boysen; J Godtfredsen; E D Andersen; B Andersen
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

6.  Screening for atrial fibrillation in primary care.

Authors:  N M Wheeldon; D I Tayler; E Anagnostou; D Cook; C Wales; G D Oakley
Journal:  Heart       Date:  1998-01       Impact factor: 5.994

7.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.

Authors:  M D Ezekowitz; S L Bridgers; K E James; N H Carliner; C L Colling; C C Gornick; H Krause-Steinrauf; J F Kurtzke; S M Nazarian; M J Radford
Journal:  N Engl J Med       Date:  1992-11-12       Impact factor: 91.245

8.  Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.

Authors:  M Sudlow; R Thomson; B Thwaites; H Rodgers; R A Kenny
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

9.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.

Authors:  S J Connolly; A Laupacis; M Gent; R S Roberts; J A Cairns; C Joyner
Journal:  J Am Coll Cardiol       Date:  1991-08       Impact factor: 24.094

10.  Warfarin for atrial fibrillation. The patient's perspective.

Authors:  M Man-Son-Hing; A Laupacis; A O'Connor; G Wells; J Lemelin; W Wood; M Dermer
Journal:  Arch Intern Med       Date:  1996-09-09
View more
  9 in total

1.  Antithrombotic treatment for atrial fibrillation. Patients must be told full details of risks of treatment.

Authors:  G Peterson
Journal:  BMJ       Date:  1999-09-11

2.  Anticoagulation for patients with atrial fibrillation. Editorial may have overinterpreted data.

Authors:  N Dudley
Journal:  BMJ       Date:  2000-09-09

Review 3.  Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Samantha MacLean; Sohail Mulla; Elie A Akl; Milosz Jankowski; Per Olav Vandvik; Shanil Ebrahim; Shelley McLeod; Neera Bhatnagar; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  How good is anticoagulation control in non-valvar atrial fibrillation? Observations on the elderly, ethnicity, patient perceptions, and understanding of AF thromboprophylaxis.

Authors:  A Choudhury; G Y H Lip
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

5.  Importance of risk communication and decision making in cardiovascular conditions in older patients: a discussion paper.

Authors:  N Dudley
Journal:  Qual Health Care       Date:  2001-09

6.  Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives.

Authors:  Pablo Alonso-Coello; Victor M Montori; M Gloria Díaz; Philip J Devereaux; Gemma Mas; Ana I Diez; Ivan Solà; Mercè Roura; Juan C Souto; Sven Oliver; Rafael Ruiz; Blanca Coll-Vinent; Ignasi Gich; Holger J Schünemann; Gordon Guyatt
Journal:  Health Expect       Date:  2014-05-12       Impact factor: 3.377

7.  A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643].

Authors:  Finlay A McAlister; Malcolm Man-Son-Hing; Sharon E Straus; William A Ghali; Paul Gibson; David Anderson; Jafna Cox; Miriam Fradette
Journal:  BMC Cardiovasc Disord       Date:  2004-05-05       Impact factor: 2.298

Review 8.  Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review.

Authors:  Thomas Wilke; Sabine Bauer; Sabrina Mueller; Thomas Kohlmann; Rupert Bauersachs
Journal:  Patient       Date:  2017-02       Impact factor: 3.883

Review 9.  Methods to Assess Patient Preferences in Old Age Pharmacotherapy - A Systematic Review.

Authors:  Annette Eidam; Anja Roth; André Lacroix; Sabine Goisser; Hanna M Seidling; Walter E Haefeli; Jürgen M Bauer
Journal:  Patient Prefer Adherence       Date:  2020-03-04       Impact factor: 2.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.